Form 4: Cytokinetics Director Nancy Wysenski Acquires Shares in Lieu of Cash Retainer

Director Nancy Wysenski acquired 118 shares of Cytokinetics Inc. common stock on October 1, 2024, in lieu of a cash retainer payment.

Summary

• On October 1, 2024, Nancy Wysenski, a director of Cytokinetics Inc. (CYTK), acquired 118 shares of common stock.
• The acquisition was made in lieu of a cash retainer payment.
• The price per share was $52.6.
• Following the transaction, Ms. Wysenski beneficially owns 22,988 shares of Cytokinetics Inc. common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of a stock acquisition by a director in lieu of a cash retainer. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• A director taking stock in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding 10% or more of a company's shares) trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The acquisition of shares by a director could be viewed positively by shareholders as it aligns the director's interests with theirs.

Key Dates